Correa RJM, et al. - Researchers report their institutional experience with renal stereotactic ablative radiotherapy (SABR) for metastatic renal cell carcinoma, focusing on technical considerations, toxicity, and clinical outcomes. They hypothesized that SABR could be a safe alternative local modality for inoperable metastatic renal cell carcinoma patients. They identified 11 patients that met study criteria. The observed median overall survival was 20.4 months. Grade 1 toxicity was observed in 5 cases. Grade 2 diarrhea and probable grade 3 nausea were observed in the patient with the largest target. Overall, minimal toxicity associated with renal SABR delivery was reported in this small cohort.